Overview

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
- The primary objective of the present study is to verify the superiority of Telecare program vs. standard SMBG program in terms of mean HbA1c value (- 0,5%) at end-point. - The secondary objectives of the study are the assessment of: total daily dose of insulin, changes in glycaemic and lipid profile, frequency of hypoglycaemias, changes in weight, health-related quality of life, cost-effectiveness of Telecare program vs. common ambulatory program; general safety (adverse event profile, other routine laboratory parameters).
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc
Metformin